Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 3c

August 6, 2020 5:13 PM EDT

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.42), $0.03 better than the analyst estimate of ($0.45).

"We are very pleased that the FDA has agreed to several proposed changes to the Phase 1 portion of AUGMENT-101 which build on emerging clinical data and help us maximize SNDX-5613's potential in as many appropriate patients as possible," said... More